Manifold prediction markets as of 2026-08-04 price OpenAI designing and manufacturing a custom AI chip by 2030 at...
Manifold prediction markets as of 2026-08-04 price OpenAI designing and manufacturing a custom AI chip by 2030 at 93.15% (market) — a high consensus that the market expects OpenAI to follow the hyperscaler path to in-house silicon.
confidence score
Strong evidence: 1 independent source class support this read.
signal brief
Manifold prediction markets as of 2026-08-04 price OpenAI designing and manufacturing a custom AI chip by 2030 at 93.15% (market) — a high consensus that the market expects OpenAI to follow the hyperscaler path to in-house silicon. The same platform prices OpenAI publicly sharing its multi-vendor portability software in 2026 at only 24.71% (market), implying the abstraction layer OpenAI built to run models across different chip providers is expected to stay proprietary. Separately, the market gives just 10.83% odds that OpenAI sells or rents AI compute to external customers by end-2026 (market), indicating OpenAI's growing compute fleet is seen as internal infrastructure rather than a neocloud business.
Taken together, the consensus paints OpenAI as vertically integrating silicon design (and eventually manufacturing), retaining a proprietary multi-vendor software stack, and keeping compute for its own models — structurally a large merchant-accelerator buyer in the near term that becomes a potential disintermediation risk for NVIDIA-class vendors later this decade. For AI-infra watchers this is a demand-side signal: continued aggressive procurement of merchant GPUs/accelerators near-term, plus a credible long-term shift to custom ASICs that would matter for TSMC, Broadcom/Marvell-type design partners, and the neocloud competitive set.
Caveats: all three inputs come from a single prediction-market platform, the custom-chip horizon is 2030, and no official OpenAI announcement or filing is cited.
What the sources said
- "Manifold consensus on 'Will OpenAI design and manufacture a custom AI chip by 2030?': YES=93.15%" — https://manifold.markets/NicholasCharette73b6/will-openai-design-and-manufacture
- "Manifold consensus on 'Will OpenAI publicly share software it developed to make its AI run on chips from different providers, in 2026?': YES=24.71%" — https://manifold.markets/Bayesian/will-openai-publicly-share-software
- "Manifold consensus on 'OpenAI sells/rents AI compute to external customers by end-2026?': YES=10.83%" — https://manifold.markets/RS/openai-sellsrents-ai-compute-to-ext
source data used
“Manifold consensus on 'Will OpenAI publicly share software it developed to make its AI run on chips from different providers, in 2026?': YES=24.71%”
“Manifold consensus on 'Will OpenAI design and manufacture a custom AI chip by 2030?': YES=93.15%”
“Manifold consensus on 'Is OpenAI's upcoming "Astra" model going to be called GPT-6?': YES=64.91%”
“Manifold consensus on 'Will any of OpenAI’s “Ten Advances in Math and Theoretical CS” be shown to be flawed by the end of August?': YES=8.45%”
“Manifold consensus on 'OpenAI abandon answer independence on ads before 2028?': YES=31.95%”
“Manifold consensus on 'OpenAI discovers the first proof of the Riemann Hypothesis before 2027?': YES=7.71%”
“Manifold consensus on 'Will OpenAI release a model marketed as GPT-6 by August 31, 2026?': YES=26.43%”
“Manifold consensus on 'Will OpenAI display ads to free tier users within one year?': YES=98.91%”
“Manifold consensus on 'Will OpenAI keep the Sora/Videos API available past September 24, 2026?': YES=8.93%”
“Manifold consensus on 'Will OpenAI be granted a trademark on "GPT" (in the U.S.)?': YES=11.64%”
“Manifold consensus on 'Will OpenAI IPO and be a publicly traded company in the United States by the end of Halloween 2026?': YES=10.59%”
“Manifold consensus on 'Will OpenAI broadly release a dedicated Cyber model to Trusted Access users by Sep 30, 2026?': YES=67.61%”
“Manifold consensus on 'OpenAI sells/rents AI compute to external customers by end-2026?': YES=10.83%”
Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.